3 No-Brainer Stocks to Buy With $200 Right Now

Motley Fool2023-11-16

For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（8）

airevo
·2023-11-16
How are you all
Reply
Like
Report
nandan
·2023-11-16
fff
Reply
Like
Report
Nomadr
·2023-11-16
F f fool lol...
Reply
Like
Report
artan supandy
·2023-11-16
I have 1 btc but i not can use,,because i not know be used aplikasion
Reply
Like
Report
bagus fahmi
·2023-11-16
No
Reply
Like
Report
Mrkoloy2
·2023-11-16
nnb777777777777777775767767777776776677777777777767
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2383524836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-16 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2383524836","market":"us","top_or_hot":-1,"title":"3 No-Brainer Stocks to Buy With $200 Right Now","media":"Motley Fool","content":"<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1914381329.SGD","symbol_name":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","start_time":0,"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","article_id":"2383524836","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","pubTimestamp":1700117777,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","ML":"MoneyLion Inc.","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","BK4527":"明星科技股","BK4166":"消费信贷","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","BK4573":"虚拟现实","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4581":"高盛持仓","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4548":"巴美列捷福持仓","GOOG":"谷歌","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","GOOGL":"谷歌A","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","BK4532":"文艺复兴科技持仓","LU0079474960.USD":"联博美国增长基金A","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","BK4534":"瑞士信贷持仓","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0061474960.USD":"天利环球焦点基金AU Acc","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"现在用200美元买3只不用动脑筋的股票","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ML":1,"GOOG":0.9,"GOOGL":0.9},"content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":242040042524840,"gmtCreate":1700128830898,"gmtModify":1700128835251,"author":{"id":"4162461213962292","authorId":"4162461213962292","name":"airevo","avatar":"https://community-static.tradeup.com/news/d063fe33be16b538bdd93f39cd95c474","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4162461213962292","authorIdStr":"4162461213962292"},"htmlText":"How are you all","listText":"How are you all","text":"How are you all","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/242040042524840","repostId":2383524836,"repostType":2,"repost":{"id":"2383524836","pubTimestamp":1700117777,"share":"https://ttm.financial/m/news/2383524836?lang=&edition=fundamental","pubTime":"2023-11-16 14:56","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","media":"Motley Fool","summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","content":"<html><head></head><body><p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:</p><ul style=\"\"><li><p>The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&amp;P 500, and Nasdaq Composite deeply into a bear market</p></li><li><p>The 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.</p></li><li><p>The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.</p></li><li><p>The 2023 &#34;bull market&#34; (it&#39;s debatable whether we&#39;re in a new bull market), which has seen the S&amp;P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.</p></li></ul><p>But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it&#39;s a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.</p><p>What&#39;s great about putting your money to work on Wall Street is that you don&#39;t need to have Bill Gates&#39; pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.</p><p>If you have $200 ready to put to work, and you&#39;re absolutely certain this isn&#39;t cash you&#39;ll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.</p><h2 id=\"id_2953721383\"><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a></h2><p>The first phenomenal value that&#39;s hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.</p><p>The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That&#39;s not particularly good news for a company that generates most of its revenue from advertising.</p><p>What <em>is</em> great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.</p><p>On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.</p><p>For decades, Google has been Alphabet&#39;s foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn&#39;t held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.</p><p>But what&#39;s even more intriguing than Google is the company&#39;s cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be &#34;disappointing&#34; year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet&#39;s high-growth segment is perfectly positioned for success.</p><p>The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it&#39;s averaged over the past five years.</p><h2 id=\"id_1231412938\"><a href=\"https://laohu8.com/S/JAZZ\">Jazz Pharmaceuticals</a></h2><p>A second no-brainer stock that&#39;s begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.</p><p>The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.</p><p>For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.</p><p>It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.</p><p>This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That&#39;s a boon to the company&#39;s operating margin.</p><p>In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.</p><p>Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW&#39;s lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.</p><p>Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years&#39; price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.</p><h2 id=\"id_3121046662\"><a href=\"https://laohu8.com/S/OKTA\">Okta</a></h2><p>The third no-brainer stock to buy with $200 right now is cybersecurity company Okta.</p><p>Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don&#39;t take time off from trying to steal consumer and enterprise information, and it&#39;s not uncommon to see cybersecurity stocks hit hard when hacks are successful.</p><p>At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.</p><p>What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta&#39;s platform is &#34;learning&#34; over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.</p><p>For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.</p><p>Perhaps the most exciting aspect of Okta&#39;s growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.</p><p>To keep with the theme, Okta&#39;s valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","GOOG":"谷歌","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4527":"明星科技股","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4166":"消费信贷","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4573":"虚拟现实","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ML":"MoneyLion Inc.","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","GOOGL":"谷歌A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4534":"瑞士信贷持仓","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383524836","content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":242037774327944,"gmtCreate":1700128276367,"gmtModify":1700128555680,"author":{"id":"4163033055619312","authorId":"4163033055619312","name":"nandan","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4163033055619312","authorIdStr":"4163033055619312"},"htmlText":"fff","listText":"fff","text":"fff","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/242037774327944","repostId":2383524836,"repostType":4,"repost":{"id":"2383524836","pubTimestamp":1700117777,"share":"https://ttm.financial/m/news/2383524836?lang=&edition=fundamental","pubTime":"2023-11-16 14:56","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","media":"Motley Fool","summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","content":"<html><head></head><body><p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:</p><ul style=\"\"><li><p>The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&amp;P 500, and Nasdaq Composite deeply into a bear market</p></li><li><p>The 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.</p></li><li><p>The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.</p></li><li><p>The 2023 &#34;bull market&#34; (it&#39;s debatable whether we&#39;re in a new bull market), which has seen the S&amp;P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.</p></li></ul><p>But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it&#39;s a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.</p><p>What&#39;s great about putting your money to work on Wall Street is that you don&#39;t need to have Bill Gates&#39; pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.</p><p>If you have $200 ready to put to work, and you&#39;re absolutely certain this isn&#39;t cash you&#39;ll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.</p><h2 id=\"id_2953721383\"><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a></h2><p>The first phenomenal value that&#39;s hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.</p><p>The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That&#39;s not particularly good news for a company that generates most of its revenue from advertising.</p><p>What <em>is</em> great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.</p><p>On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.</p><p>For decades, Google has been Alphabet&#39;s foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn&#39;t held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.</p><p>But what&#39;s even more intriguing than Google is the company&#39;s cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be &#34;disappointing&#34; year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet&#39;s high-growth segment is perfectly positioned for success.</p><p>The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it&#39;s averaged over the past five years.</p><h2 id=\"id_1231412938\"><a href=\"https://laohu8.com/S/JAZZ\">Jazz Pharmaceuticals</a></h2><p>A second no-brainer stock that&#39;s begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.</p><p>The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.</p><p>For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.</p><p>It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.</p><p>This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That&#39;s a boon to the company&#39;s operating margin.</p><p>In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.</p><p>Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW&#39;s lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.</p><p>Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years&#39; price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.</p><h2 id=\"id_3121046662\"><a href=\"https://laohu8.com/S/OKTA\">Okta</a></h2><p>The third no-brainer stock to buy with $200 right now is cybersecurity company Okta.</p><p>Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don&#39;t take time off from trying to steal consumer and enterprise information, and it&#39;s not uncommon to see cybersecurity stocks hit hard when hacks are successful.</p><p>At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.</p><p>What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta&#39;s platform is &#34;learning&#34; over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.</p><p>For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.</p><p>Perhaps the most exciting aspect of Okta&#39;s growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.</p><p>To keep with the theme, Okta&#39;s valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","GOOG":"谷歌","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4527":"明星科技股","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4166":"消费信贷","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4573":"虚拟现实","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ML":"MoneyLion Inc.","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","GOOGL":"谷歌A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4534":"瑞士信贷持仓","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383524836","content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":242028395257856,"gmtCreate":1700126108919,"gmtModify":1700126240378,"author":{"id":"3567256937368628","authorId":"3567256937368628","name":"Nomadr","avatar":"https://static.tigerbbs.com/87ffa292cf6c6bac6572beb240597005","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3567256937368628","authorIdStr":"3567256937368628"},"htmlText":"F f fool lol...","listText":"F f fool lol...","text":"F f fool lol...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/242028395257856","repostId":2383524836,"repostType":4,"repost":{"id":"2383524836","pubTimestamp":1700117777,"share":"https://ttm.financial/m/news/2383524836?lang=&edition=fundamental","pubTime":"2023-11-16 14:56","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","media":"Motley Fool","summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","content":"<html><head></head><body><p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:</p><ul style=\"\"><li><p>The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&amp;P 500, and Nasdaq Composite deeply into a bear market</p></li><li><p>The 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.</p></li><li><p>The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.</p></li><li><p>The 2023 &#34;bull market&#34; (it&#39;s debatable whether we&#39;re in a new bull market), which has seen the S&amp;P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.</p></li></ul><p>But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it&#39;s a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.</p><p>What&#39;s great about putting your money to work on Wall Street is that you don&#39;t need to have Bill Gates&#39; pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.</p><p>If you have $200 ready to put to work, and you&#39;re absolutely certain this isn&#39;t cash you&#39;ll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.</p><h2 id=\"id_2953721383\"><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a></h2><p>The first phenomenal value that&#39;s hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.</p><p>The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That&#39;s not particularly good news for a company that generates most of its revenue from advertising.</p><p>What <em>is</em> great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.</p><p>On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.</p><p>For decades, Google has been Alphabet&#39;s foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn&#39;t held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.</p><p>But what&#39;s even more intriguing than Google is the company&#39;s cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be &#34;disappointing&#34; year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet&#39;s high-growth segment is perfectly positioned for success.</p><p>The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it&#39;s averaged over the past five years.</p><h2 id=\"id_1231412938\"><a href=\"https://laohu8.com/S/JAZZ\">Jazz Pharmaceuticals</a></h2><p>A second no-brainer stock that&#39;s begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.</p><p>The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.</p><p>For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.</p><p>It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.</p><p>This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That&#39;s a boon to the company&#39;s operating margin.</p><p>In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.</p><p>Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW&#39;s lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.</p><p>Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years&#39; price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.</p><h2 id=\"id_3121046662\"><a href=\"https://laohu8.com/S/OKTA\">Okta</a></h2><p>The third no-brainer stock to buy with $200 right now is cybersecurity company Okta.</p><p>Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don&#39;t take time off from trying to steal consumer and enterprise information, and it&#39;s not uncommon to see cybersecurity stocks hit hard when hacks are successful.</p><p>At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.</p><p>What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta&#39;s platform is &#34;learning&#34; over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.</p><p>For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.</p><p>Perhaps the most exciting aspect of Okta&#39;s growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.</p><p>To keep with the theme, Okta&#39;s valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","GOOG":"谷歌","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4527":"明星科技股","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4166":"消费信贷","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4573":"虚拟现实","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ML":"MoneyLion Inc.","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","GOOGL":"谷歌A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4534":"瑞士信贷持仓","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383524836","content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":242024197120016,"gmtCreate":1700124945678,"gmtModify":1700124958540,"author":{"id":"4161403759653922","authorId":"4161403759653922","name":"artan supandy","avatar":"https://community-static.tradeup.com/news/1b994f515ce3154dfebeee80298531ff","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4161403759653922","authorIdStr":"4161403759653922"},"htmlText":"I have 1 btc but i not can use,,because i not know be used aplikasion","listText":"I have 1 btc but i not can use,,because i not know be used aplikasion","text":"I have 1 btc but i not can use,,because i not know be used aplikasion","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/242024197120016","repostId":2383524836,"repostType":4,"repost":{"id":"2383524836","pubTimestamp":1700117777,"share":"https://ttm.financial/m/news/2383524836?lang=&edition=fundamental","pubTime":"2023-11-16 14:56","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","media":"Motley Fool","summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","content":"<html><head></head><body><p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:</p><ul style=\"\"><li><p>The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&amp;P 500, and Nasdaq Composite deeply into a bear market</p></li><li><p>The 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.</p></li><li><p>The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.</p></li><li><p>The 2023 &#34;bull market&#34; (it&#39;s debatable whether we&#39;re in a new bull market), which has seen the S&amp;P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.</p></li></ul><p>But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it&#39;s a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.</p><p>What&#39;s great about putting your money to work on Wall Street is that you don&#39;t need to have Bill Gates&#39; pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.</p><p>If you have $200 ready to put to work, and you&#39;re absolutely certain this isn&#39;t cash you&#39;ll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.</p><h2 id=\"id_2953721383\"><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a></h2><p>The first phenomenal value that&#39;s hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.</p><p>The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That&#39;s not particularly good news for a company that generates most of its revenue from advertising.</p><p>What <em>is</em> great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.</p><p>On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.</p><p>For decades, Google has been Alphabet&#39;s foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn&#39;t held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.</p><p>But what&#39;s even more intriguing than Google is the company&#39;s cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be &#34;disappointing&#34; year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet&#39;s high-growth segment is perfectly positioned for success.</p><p>The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it&#39;s averaged over the past five years.</p><h2 id=\"id_1231412938\"><a href=\"https://laohu8.com/S/JAZZ\">Jazz Pharmaceuticals</a></h2><p>A second no-brainer stock that&#39;s begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.</p><p>The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.</p><p>For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.</p><p>It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.</p><p>This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That&#39;s a boon to the company&#39;s operating margin.</p><p>In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.</p><p>Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW&#39;s lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.</p><p>Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years&#39; price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.</p><h2 id=\"id_3121046662\"><a href=\"https://laohu8.com/S/OKTA\">Okta</a></h2><p>The third no-brainer stock to buy with $200 right now is cybersecurity company Okta.</p><p>Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don&#39;t take time off from trying to steal consumer and enterprise information, and it&#39;s not uncommon to see cybersecurity stocks hit hard when hacks are successful.</p><p>At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.</p><p>What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta&#39;s platform is &#34;learning&#34; over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.</p><p>For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.</p><p>Perhaps the most exciting aspect of Okta&#39;s growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.</p><p>To keep with the theme, Okta&#39;s valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","GOOG":"谷歌","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4527":"明星科技股","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4166":"消费信贷","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4573":"虚拟现实","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ML":"MoneyLion Inc.","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","GOOGL":"谷歌A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4534":"瑞士信贷持仓","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383524836","content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":242001771692104,"gmtCreate":1700119649801,"gmtModify":1700120045178,"author":{"id":"4163197941915412","authorId":"4163197941915412","name":"bagus fahmi","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4163197941915412","authorIdStr":"4163197941915412"},"htmlText":"No","listText":"No","text":"No","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/242001771692104","repostId":2383524836,"repostType":4,"repost":{"id":"2383524836","pubTimestamp":1700117777,"share":"https://ttm.financial/m/news/2383524836?lang=&edition=fundamental","pubTime":"2023-11-16 14:56","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","media":"Motley Fool","summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","content":"<html><head></head><body><p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:</p><ul style=\"\"><li><p>The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&amp;P 500, and Nasdaq Composite deeply into a bear market</p></li><li><p>The 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.</p></li><li><p>The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.</p></li><li><p>The 2023 &#34;bull market&#34; (it&#39;s debatable whether we&#39;re in a new bull market), which has seen the S&amp;P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.</p></li></ul><p>But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it&#39;s a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.</p><p>What&#39;s great about putting your money to work on Wall Street is that you don&#39;t need to have Bill Gates&#39; pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.</p><p>If you have $200 ready to put to work, and you&#39;re absolutely certain this isn&#39;t cash you&#39;ll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.</p><h2 id=\"id_2953721383\"><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a></h2><p>The first phenomenal value that&#39;s hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.</p><p>The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That&#39;s not particularly good news for a company that generates most of its revenue from advertising.</p><p>What <em>is</em> great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.</p><p>On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.</p><p>For decades, Google has been Alphabet&#39;s foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn&#39;t held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.</p><p>But what&#39;s even more intriguing than Google is the company&#39;s cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be &#34;disappointing&#34; year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet&#39;s high-growth segment is perfectly positioned for success.</p><p>The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it&#39;s averaged over the past five years.</p><h2 id=\"id_1231412938\"><a href=\"https://laohu8.com/S/JAZZ\">Jazz Pharmaceuticals</a></h2><p>A second no-brainer stock that&#39;s begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.</p><p>The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.</p><p>For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.</p><p>It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.</p><p>This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That&#39;s a boon to the company&#39;s operating margin.</p><p>In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.</p><p>Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW&#39;s lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.</p><p>Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years&#39; price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.</p><h2 id=\"id_3121046662\"><a href=\"https://laohu8.com/S/OKTA\">Okta</a></h2><p>The third no-brainer stock to buy with $200 right now is cybersecurity company Okta.</p><p>Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don&#39;t take time off from trying to steal consumer and enterprise information, and it&#39;s not uncommon to see cybersecurity stocks hit hard when hacks are successful.</p><p>At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.</p><p>What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta&#39;s platform is &#34;learning&#34; over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.</p><p>For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.</p><p>Perhaps the most exciting aspect of Okta&#39;s growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.</p><p>To keep with the theme, Okta&#39;s valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","GOOG":"谷歌","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4527":"明星科技股","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4166":"消费信贷","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4573":"虚拟现实","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ML":"MoneyLion Inc.","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","GOOGL":"谷歌A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4534":"瑞士信贷持仓","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383524836","content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":242000859844664,"gmtCreate":1700119246766,"gmtModify":1700119328127,"author":{"id":"4158984634608852","authorId":"4158984634608852","name":"Mrkoloy2","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4158984634608852","authorIdStr":"4158984634608852"},"htmlText":"nnb777777777777777775767767777776776677777777777767","listText":"nnb777777777777777775767767777776776677777777777767","text":"nnb777777777777777775767767777776776677777777777767","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/242000859844664","repostId":2383524836,"repostType":2,"repost":{"id":"2383524836","pubTimestamp":1700117777,"share":"https://ttm.financial/m/news/2383524836?lang=&edition=fundamental","pubTime":"2023-11-16 14:56","market":"us","language":"en","title":"3 No-Brainer Stocks to Buy With $200 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2383524836","media":"Motley Fool","summary":"A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses.","content":"<html><head></head><body><p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:</p><ul style=\"\"><li><p>The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&amp;P 500, and Nasdaq Composite deeply into a bear market</p></li><li><p>The 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.</p></li><li><p>The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.</p></li><li><p>The 2023 &#34;bull market&#34; (it&#39;s debatable whether we&#39;re in a new bull market), which has seen the S&amp;P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.</p></li></ul><p>But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it&#39;s a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.</p><p>What&#39;s great about putting your money to work on Wall Street is that you don&#39;t need to have Bill Gates&#39; pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.</p><p>If you have $200 ready to put to work, and you&#39;re absolutely certain this isn&#39;t cash you&#39;ll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.</p><h2 id=\"id_2953721383\"><a href=\"https://laohu8.com/S/GOOGL\">Alphabet</a></h2><p>The first phenomenal value that&#39;s hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.</p><p>The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That&#39;s not particularly good news for a company that generates most of its revenue from advertising.</p><p>What <em>is</em> great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.</p><p>On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.</p><p>For decades, Google has been Alphabet&#39;s foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn&#39;t held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.</p><p>But what&#39;s even more intriguing than Google is the company&#39;s cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be &#34;disappointing&#34; year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet&#39;s high-growth segment is perfectly positioned for success.</p><p>The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it&#39;s averaged over the past five years.</p><h2 id=\"id_1231412938\"><a href=\"https://laohu8.com/S/JAZZ\">Jazz Pharmaceuticals</a></h2><p>A second no-brainer stock that&#39;s begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.</p><p>The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.</p><p>For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.</p><p>It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.</p><p>This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That&#39;s a boon to the company&#39;s operating margin.</p><p>In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.</p><p>Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW&#39;s lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.</p><p>Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years&#39; price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.</p><h2 id=\"id_3121046662\"><a href=\"https://laohu8.com/S/OKTA\">Okta</a></h2><p>The third no-brainer stock to buy with $200 right now is cybersecurity company Okta.</p><p>Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don&#39;t take time off from trying to steal consumer and enterprise information, and it&#39;s not uncommon to see cybersecurity stocks hit hard when hacks are successful.</p><p>At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.</p><p>What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta&#39;s platform is &#34;learning&#34; over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.</p><p>For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.</p><p>Perhaps the most exciting aspect of Okta&#39;s growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.</p><p>To keep with the theme, Okta&#39;s valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 No-Brainer Stocks to Buy With $200 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 No-Brainer Stocks to Buy With $200 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-16 14:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial ...</p>\n\n<a href=\"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","GOOG":"谷歌","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK4527":"明星科技股","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4166":"消费信贷","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0149725797.USD":"汇丰美国股市经济规模基金","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4573":"虚拟现实","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4581":"高盛持仓","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4548":"巴美列捷福持仓","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ML":"MoneyLion Inc.","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","IE00BJTD4V19.USD":"NEUBERGER BERMAN US LONG SHORT EQUITY \"A1\" (USD) ACC","GOOGL":"谷歌A","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4532":"文艺复兴科技持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","BK4534":"瑞士信贷持仓","LU0494093205.USD":"贝莱德ESG灵活多元资产A2 USD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC"},"source_url":"https://www.fool.com/investing/2023/11/15/3-no-brainer-stocks-to-buy-with-200-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2383524836","content_text":"For nearly four years, Wall Street has been a roller coaster for investors. In order, they have contended with:The historic COVID-19 crash of February-March 2020 that sent the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite deeply into a bear marketThe 2021 bull market that bordered on euphoria and sent growth-stock valuations into the stratosphere.The 2022 bear market, which saw the growth-driven Nasdaq Composite lose a third of its value.The 2023 \"bull market\" (it's debatable whether we're in a new bull market), which has seen the S&P 500 and Nasdaq Composite meaningfully rally from their 2022 bear market lows.But in spite of this year-to-date rally, the major indexes still sit well below their 2021 record-closing highs. Though this might be disappointing to short-term traders, it's a red carpet opportunity for long-term investors to buy stakes in great companies at a discount.What's great about putting your money to work on Wall Street is that you don't need to have Bill Gates' pocketbook to generate wealth. With most online brokerages doing away with minimum-deposit requirements and commissions for common-stock trades on major U.S. exchanges, any amount of money -- even $200 -- can be the perfect amount to invest.If you have $200 ready to put to work, and you're absolutely certain this isn't cash you'll need to pay bills or cover emergencies, the following three stocks stand out as no-brainer buys right now.AlphabetThe first phenomenal value that's hiding in plain sight, which you can add to your portfolio with $200 right now, is Alphabet. This is the parent company of widely used internet search engine Google and popular streaming platform YouTube.The primary reason Alphabet has backed off of its record-closing high from two years ago is uncertainty about the U.S. economy. Though the unemployment rate is historically low, a couple of money-based predictive tools signal trouble ahead. That's not particularly good news for a company that generates most of its revenue from advertising.What is great news for Alphabet is that recessions tend to be short-lived. Only 3 of 12 recessions since the end of World War II have lasted 12 months, with none surpassing 18 months.On the other hand, periods of expansion typically endure for multiple years, if not more than a decade. This means Alphabet is going to command exceptional ad-pricing power more often than not.For decades, Google has been Alphabet's foundation. In October, Google accounted for nearly 92% of worldwide internet search. In fact, Google hasn't held less than a 90% monthly share of global search in over eight years. As the clear go-to for merchants looking to target consumers, Alphabet should have no trouble steadily growing its operating cash flow from its core segment.But what's even more intriguing than Google is the company's cloud infrastructure service Google Cloud. Despite what Wall Street perceived to be \"disappointing\" year-over-year sales growth of 22.5% in the September-ended quarter, Google Cloud has delivered three consecutive quarters of operating profit after multiple years of losses. With cloud spending still in its early stages, Alphabet's high-growth segment is perfectly positioned for success.The final reason to pile into Alphabet is its valuation. Shares can be purchased right now for less than 14 times forward-year cash flow, which is notably lower than the 18 multiple it's averaged over the past five years.Jazz PharmaceuticalsA second no-brainer stock that's begging to be bought with $200 right now is specialty biotech Jazz Pharmaceuticals.The biggest concern for Jazz is the potential loss of exclusivity for its blockbuster drugs. But thanks to ongoing innovation, diversification, and acquisitions, the company has the catalysts necessary to push past this near-term skepticism.For years, Jazz has been reaping the benefits of its sodium oxybate franchise Xyrem for various sleep disorders, including narcolepsy. But with generic versions being approved by the Food and Drug Administration (FDA), Jazz has had to rely on its innovation to secure its operating cash flow.It responded by developing Xywav, another sleep disorder therapy, but one with 92% less sodium than Xyrem. For patients with higher cardiovascular risk factors, Xywav is an improvement. More importantly, it will allow Jazz to hang on to its cash flow for years to come.This is a good time to mention that Jazz has done a particularly good job of growing its oxybate franchise by increasing the price of its novel therapies. Since Jazz is primarily focused on developing drugs that target orphan and rare diseases, it typically faces little or no pushback on its list prices from health insurers. That's a boon to the company's operating margin.In terms of diversification, Jazz expects its oncology segment to reach roughly $1 billion in full-year sales in 2023, with acute lymphoblastic leukemia and lymphoblastic lymphoma drug Rylaze doing most of the heavy lifting.Meanwhile, Jazz also completed the acquisition of cannabidiol-based drug developer GW Pharmaceuticals in May 2021. GW's lead drug, Epidiolex, has the potential to top $1 billion in peak annual sales with label expansion opportunities.Best of all, the price is right with Jazz. Shares are currently trading for roughly 6 times next years' price-to-earnings (P/E) ratio, which is historically cheap and fully bakes in any patent-cliff concerns.OktaThe third no-brainer stock to buy with $200 right now is cybersecurity company Okta.Shares of Okta have been clobbered over the past month following the hack of a support system that allowed access to sensitive user information. Hackers don't take time off from trying to steal consumer and enterprise information, and it's not uncommon to see cybersecurity stocks hit hard when hacks are successful.At the same time, this ongoing battle against hackers represents a surefire opportunity for Okta to generate steady operating cash flow. Any business with an online or cloud-based presence needs to protect its sensitive information, which has led to an increased reliance on third-party providers like Okta.What has made Okta special is its focus on identity verification. Its platform is cloud-native and reliant on artificial intelligence (AI). The incorporation of machine learning (ML) technology ensures that Okta's platform is \"learning\" over time. Though it did suffer a breach in October, AI and ML will help the platform become more efficient at proactively recognizing and responding to threats.For the moment, Okta is merely scratching the surface of its addressable market in identity verification. In November 2022, it pegged its addressable market at $80 billion, which includes $30 billion for consumer identity. With fiscal 2024 sales expected to come in at $2.22 billion, the company has plenty of runway to sustain a double-digit growth rate.Perhaps the most exciting aspect of Okta's growth is its acquisition of Auth0, which closed in February 2022. Despite higher-than-anticipated near-term acquisition costs, the Auth0 deal should be a big-time winner for Okta. It targets the lucrative consumer identity market, and will provide Okta with ample sales opportunities outside the United States.To keep with the theme, Okta's valuation is also deceptively attractive. Even though its forward P/E of 45 might appear high, a consensus five-year annualized growth rate of 25% brings its price/earnings-to-growth ratio well below 2.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":20,"commentSize":8,"repostSize":3,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}